Education
About Us
Working with TipRanks
Follow Us
Oncopeptides AB (SE:ONCO)
:ONCO
ONCO Stock Chart & Stats
kr4.88
>-kr0.01(-0.39%)
At close: 4:00 PM EST
kr4.88
>-kr0.01(-0.39%)
Day’s Range― - ―
52-Week Rangekr1.04 - kr6.56
Previous CloseN/A
Volume80.98K
Average Volume (3M)2.28M
Market Cap
kr770.53M
Enterprise Valuekr580.32M
Total Cash (Recent Filing)kr70.15M
Total Debt (Recent Filing)kr124.23M
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Feb 19, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding258,567,470
10 Day Avg. Volume1,913,694
30 Day Avg. Volume2,284,999
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.78
Price to Sales (P/S)8.20
P/FCF Ratio-1.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsecutive strong top-line growth indicates durable commercial traction for Pepaxti in Europe, reflecting expanding market access and adoption. Sustained revenue acceleration supports scaling of fixed costs, strengthens negotiating leverage with partners, and improves the path to targeted profitability by end-2026.
Very High Gross MarginAn exceptionally high gross margin implies favorable product economics and low variable cost per sale. If maintained, revenue growth will flow through to operating leverage quickly, enabling margins expansion and making profitability achievable once operating expenses are controlled and scale is sustained.
Strengthened Cash RunwayA materially strengthened cash position following an oversubscribed rights issue provides a multi-month runway to execute commercialization, pursue partnerships, and invest in market access. It reduces immediate refinancing risk and signals investor support, supporting strategy execution over the next 2–6 months.
Bears Say
Ongoing Net LossesPersistent net losses show the company remains unprofitable despite revenue gains, requiring continued spending and external funding. Losses—partly driven by noncash items—underscore that operating profitability has not been achieved and that achieving the stated 2026 profitability target depends on sustained revenue and cost control.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flow indicate the core business is not yet generating cash, forcing reliance on capital markets. This structural cash burn elevates dilution or leverage risk, constrains reinvestment capacity, and weakens resilience to commercial setbacks absent sustained margin and sales improvement.
Elevated Liabilities And Weakened Equity RatioA leveraged balance sheet with deteriorating equity financing reduces financial flexibility and raises vulnerability to revenue hiccups. Elevated liabilities can increase funding costs and restrict strategic options like M&A or large commercial investments until equity metrics improve or cash generation turns positive.
Oncopeptides AB News
ONCO FAQ
What was Oncopeptides AB’s price range in the past 12 months?
Oncopeptides AB lowest stock price was kr1.04 and its highest was kr6.56 in the past 12 months.
What is Oncopeptides AB’s market cap?
Oncopeptides AB’s market cap is kr770.53M.
When is Oncopeptides AB’s upcoming earnings report date?
Oncopeptides AB’s upcoming earnings report date is Feb 19, 2026 which is tomorrow.
How were Oncopeptides AB’s earnings last quarter?
Oncopeptides AB released its earnings results on Nov 05, 2025. The company reported -kr0.27 earnings per share for the quarter, beating the consensus estimate of -kr2.425 by kr2.155.
Is Oncopeptides AB overvalued?
According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued.
Does Oncopeptides AB pay dividends?
Oncopeptides AB does not currently pay dividends.
What is Oncopeptides AB’s EPS estimate?
Oncopeptides AB’s EPS estimate is -0.19.
How many shares outstanding does Oncopeptides AB have?
Oncopeptides AB has 258,567,470 shares outstanding.
What happened to Oncopeptides AB’s price movement after its last earnings report?
Oncopeptides AB reported an EPS of -kr0.27 in its last earnings report, beating expectations of -kr2.425. Following the earnings report the stock price went down -13.472%.
Which hedge fund is a major shareholder of Oncopeptides AB?
Currently, no hedge funds are holding shares in SE:ONCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncopeptides AB
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Xspray Pharma AB
―
Active Biotech AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---